Healthfirst
Provides healthcare coverage to individuals & families in the NY service area.
Based in NY
🤖
AI Overview
With $1.6M in lobbying spend across 29 quarterly filings, Healthfirst is a significant lobbying presence.
$1.6M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
2
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $300K |
| 2019 | $210K |
| 2020 | $150K |
| 2021 | $150K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $150K |
Lobbying Firms
WELSH ROSE, LLC
What They Lobby For
- Issues related to market stabilization.
- Issues related to Medicaid reform. Issues related to Medicare special needs plans. Issues related to Medicare Advantage.
- Issues related to Medicaid reform. Issues related to Medicare Advantage.
- Issues related to Medicaid reform. Issues related to Medicare Advantage. Issues related to H.R.748/S.3548, CARES Act.
- Issues related to Medicaid reform. Issues related to Medicare Advantage. Issues related to H.R.748/S.3548, CARES Act. H.R. 133, the Consolidated Appropriations Act of 2021.
- H.R. 1, One Big Beautiful Bill Act, as it relates to Medicaid reform and Medicare Advantage.
- H.R. 1, One Big Beautiful Bill Act, as it relates to exchange tax credit and enrollment policies.
- H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to Medicaid reform and Medicare Advantage.
- H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act and exchange tax credit and enrollment policies.
- Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to Medicaid reform and Medicare Advantage.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.